Mixed Hyperlipidemia
10
0
0
7
Key Insights
Highlights
Success Rate
88% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 17/100
10.0%
1 terminated out of 10 trials
87.5%
+1.0% vs benchmark
60%
6 trials in Phase 3/4
43%
3 of 7 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 7 completed trials
Clinical Trials (10)
Efficacy and Safety of SHR-1209 Combined With Lipid-lowering Agents in Patients With Hypercholesterolemia
Phase 2 Dose-Ranging Efficacy and Safety Trial of SCH 900271 in Participants With Primary Hypercholesterolemia or Mixed Hyperlipidemia (P05675)
Lipid Efficacy and Safety in Participants With Mixed Hyperlipidemia (MK-0524B-024)
Lipid Efficacy Study (0524B-022)(COMPLETED)
A Pilot Study to Evaluate the Lipid Effects of TRIA-662
A Study to Evaluate the Effects of Laropiprant on the Antiplatelet Effects of Clopidogrel and Aspirin in Combination (MK-0524A-114)(COMPLETED)
Efficacy and Safety of Fenofibrate Added on to Atorvastatin Compared With Atorvastatin
Comparison of the Efficacy and Safety of AtorVastatin mOnotherapy vs. Combination Atorvastatin/Fenofibric Acid
Carotid B-mode Ultrasound Study to Compare Anti-Atherosclerotic Effect of Torcetrapib/Atorvastatin to Atorvastatin.
Efficacy Study of Extended-Release Niacin/Lovastatin Versus Usual Care